
IASLC 2026 World Conference on Lung Cancer


SEPTEMBER 12 – 15, 2026 | SEOUL, REPUBLIC OF KOREA


Efficacy and Safety of GFH375 in Advanced *KRAS*^{G12D} Mutant Non-Small Cell Lung Cancer (NSCLC) Patients


Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine--Shanghai, China


Shun Lu, Ziming Li, Xinghao Ai, Peng Chen, Wenxiu Yao, Hong Zong, Lin Wu, Tongmei Zhang, Jianbo He, Qitao Yu, Zuoxing Niu, Yuping Sun, Jian Fang, Jianxin Xue, Anna Li, Kejing Tang, Lingjun Zhu, Zhengbo Song, Ying Yuan, Meili Sun, Lin Zhao, Yingying Du, Yu Wang, Haige Shen, Huaqiang Zhu, Chanli Zheng, Shuang Wang, Zhao Cui



KRAS^{G12D}
NSCLC previously treated with ICI and/or platinum-based chemo therapies





100
50
-50
-100
e from baseline (%)
Best percent
ge chang
Prior lines of therapy



Prior lines of therapy
Duration of treatment (months)
0
2
4
6
8
10
12
14
16
18
20
PR
SD
PD
NE
Death
Ongoing



1.00
0.75
0.50
0.25
0.00



Treatment-Emergent AE
Treatment-Related AE
Diarrhoea
Nausea
Aspartateaminotransferase increased
Anaemia
Hypertriglyceridaemia
Neutrophilcount decreased
Decreased appetite
Amylase increased
Proteinuria
Hyponatraemia
Asthenia
Hyperglycaemia
Gamma-glutam



Genes frequency in tissue and ctDNA


KRASG12D (n=43)
6.8
8.3
TP53 (n=30)
5.6
Not reached
STK11 (n=10)
5.4
8.3
KEAP1 (n=7)
1.5
8.3
CDKN2A (n=7)
5.4
8.3
Median PFS, months
Altered
Nonaltered


KRASG12D status
Undetectable
Detectable
1.00
0.75
KRASG12D
KRASG12D
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Undetectable 30 29 24 22 21 20 19 16 16 10 8 7 5 5 3 3 2
Detectable 43 43 37 32 30 27 18 13 13 11 8 8 5 4 2 2 1


1.00
STK11/KEAP1/TP53/
CDKN2A
STK11/KEAP1/TP53/
CDKN2A
0.75
0.25
0.00
8 9 10 11 12 13 14 15 16
0 1 2 3 4 5 6 7
Nonaltered 38 38 33 31 30 28 24 20
Altered 35 34 28 23 21 19 13 9

Thank You.